151 related articles for article (PubMed ID: 8184598)
1. Development and small-scale production of a severely heated factor VIII concentrate.
Knevelman A; de Wit HJ; Potstra P; vd Does JA
Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
[TBL] [Abstract][Full Text] [Related]
2. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
[TBL] [Abstract][Full Text] [Related]
3. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
4. Severely heated therapeutic factor VIII concentrate of high specific activity.
Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
[TBL] [Abstract][Full Text] [Related]
5. [Factor VIII concentrate, highly purified and heated in solution (author's transl)].
Heimburger N; Schwinn H; Gratz P; Lüben G; Kumpe G; Herchenhan B
Arzneimittelforschung; 1981; 31(4):619-22. PubMed ID: 6788045
[TBL] [Abstract][Full Text] [Related]
6. Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.
Allersma DP; Roeffen E; Van der Does JA; Briët E
Pharm Weekbl Sci; 1991 Feb; 13(1):18-23. PubMed ID: 1903526
[TBL] [Abstract][Full Text] [Related]
7. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
[TBL] [Abstract][Full Text] [Related]
8. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
[TBL] [Abstract][Full Text] [Related]
9. Modified glycine precipitation technique for the preparation of factor VIII concentrate of high purity and high stability.
Brodniewicz-Proba T; Beauregard D
Vox Sang; 1987; 52(1-2):10-4. PubMed ID: 3111087
[TBL] [Abstract][Full Text] [Related]
10. Controlled pore glass factor VIII concentrate: influence of heat treatment.
Ockelford PA; Benny AG; Berry EW; Johns AS; Woodfield DG
Pathology; 1987 Jan; 19(1):56-7. PubMed ID: 3108838
[TBL] [Abstract][Full Text] [Related]
11. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
[TBL] [Abstract][Full Text] [Related]
12. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
Branović K; Gebauer B; Trescec A; Benko B
Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
[TBL] [Abstract][Full Text] [Related]
13. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
[TBL] [Abstract][Full Text] [Related]
14. Large-scale preparation of a highly purified solvent-detergent treated factor VIII concentrate.
Myers R; Wickerhauser M; Charamella L; Simon L; Nummy W; Brodniewicz-Proba T
Vox Sang; 1991; 60(3):141-7. PubMed ID: 1907414
[TBL] [Abstract][Full Text] [Related]
15. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
16. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K
N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917
[TBL] [Abstract][Full Text] [Related]
17. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
18. Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates.
Allersma DP; Swüste F; Briët E; Van der Does JA
Pharm Weekbl Sci; 1991 Feb; 13(1):24-31. PubMed ID: 1903527
[TBL] [Abstract][Full Text] [Related]
19. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
[TBL] [Abstract][Full Text] [Related]
20. Preparation of antihemophilic factor from indated plasma.
Wickerhauser M
Transfusion; 1976; 16(4):345-50. PubMed ID: 951729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
